Evaluation of an Updated Dexamethasone Posterior Segment Drug Delivery System Applicator in Participants With Macular Edema Due to Retinal Diseases
Latest Information Update: 01 Mar 2023
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema
- Focus Adverse reactions; Registrational
- Sponsors AbbVie; Allergan
- 11 Feb 2022 Status changed from recruiting to completed.
- 09 Feb 2022 Planned End Date changed from 14 Jan 2022 to 22 Mar 2022.
- 09 Feb 2022 Planned primary completion date changed from 12 Jan 2022 to 22 Mar 2022.